← FDA DRUG APPROVALS
FDA ANDA · ANDA090718
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Sponsor: GLENMARK PHARMS
APPLICATION
ANDA090718
TYPE
ANDA
ORIGINAL APPROVAL
2010-03-17
LATEST ACTION
2020-08-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, MOEXIPRIL HYDROCHLORIDE 15MG · TABLET · ORAL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 12.5MG, MOEXIPRIL HYDROCHLORIDE 7.5MG · TABLET · ORAL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 12.5MG, MOEXIPRIL HYDROCHLORIDE 15MG · TABLET · ORAL
Approval history
2020-08-20Labeling · Supplement 7 · standardAP
2013-12-13Labeling · Supplement 6 · standardAP
2013-12-13Labeling · Supplement 3AP
2011-11-29Labeling · Supplement 2AP
2011-07-26Labeling · Supplement 1AP
2010-03-17OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.